PRECLINICAL MOUSE: CENTRAL NERVOUS SYSTEM CANCERS

四名调查员组成了这项建议的核心，他们每人都为联合体带来了专门知识。 PI，Terry货车Dyke博士，利用小鼠操作策略研究癌症已有16年。 在分析肿瘤抑制因子p53和pRb的过程中，她的实验室使用转基因和敲除策略建立了几种肿瘤模型。 埃里克·霍兰德博士是一名神经外科医生和新成立的调查员。在Varmus实验室担任研究助理期间，他开发了一种新方法，用于小鼠癌症基因的短期体细胞分析。 他在确定生长因子在神经胶质细胞生长和迁移中的作用方面取得了重大进展。 大卫路易斯博士是一位神经病理学家，对人类神经胶质瘤的遗传病变感兴趣。 最近，他在19号染色体上定位了一个新的胶质瘤特异性肿瘤抑制基因（TSG）。 R Jude Samulski博士是基因治疗领域的领导者，他开发了病毒载体，这些载体在体内体细胞基因传递方面表现出巨大的潜力。 该提案的主要实验目标是开发准确反映人类神经胶质瘤阶段和类别的小鼠模型。 这里开发和利用的许多策略也可以更广泛地应用于其他CNS癌症模型。 货车戴克博士的实验室已经开发出一种脉络丛（CP）肿瘤模型，在组织学上与人类疾病相似。 它描述了CP模型及其推导方法。 霍兰德博士的工作将通过将体细胞基因导入小鼠大脑来确定在人类神经胶质瘤中观察到的遗传变化的细胞反应。 货车戴克实验室将利用生殖系修饰策略来产生具有类似改变的小鼠品系。 货车戴克和霍兰德之间的密切相互作用将有助于快速鉴定将被工程化到种系中的遗传变化。 这些实验室的初步结果表明，在小鼠中产生神经胶质瘤样病变方面取得了重大进展。 项目4将建立一种胶质细胞特异性靶向失活的pTEN基因，一种常见的失活在人类胶质瘤。 这只小鼠将用于模型推导，Louis博士将评估小鼠中诱导的病理学与人类中观察到的病理学相似的程度。 将对人类和小鼠样本进行组织学和遗传学研究。 路易斯实验室将完成胶质瘤特异性TSG的分离，货车戴克实验室将使用基因靶向策略来评估其肿瘤抑制功能。 最后，我们将在现有和正在开发的小鼠模型中研究有限数量的治疗策略，包括Holland博士的EGFR靶向策略和Samulski博士和货车Dyke博士的抗血管生成基因治疗。

Four investigators, each of who bring special expertise to the consortium, comprise the core of this proposal. The PI, Dr. Terry Van Dyke, has utilized mouse manipulation strategies to study cancer for 16 years. In the course of analyzing the tumor suppressors p53 and pRb, her lab has established several tumor models using transgenic and knock-out strategies. Dr. Eric Holland is a Neurosurgeon and newly established investigator. While a research associate in the Varmus lab, he developed a novel approach for short term somatic analysis of cancer genes in the mouse. He has made significant progress in defining growth factor roles in glial cell growth and migration. Dr David Louis is a Neuropathologist interested in the genetic lesions of human glioma. Most recently he mapped a new glioma specific tumor suppressor gene (TSG) on chromosome 19. Dr R Jude Samulski (UNC), a leader in genetic therapy, has developed viral vectors that show great potential for somatic gene delivery in vivo. The major experimental goal of this proposal is to develop mouse models that accurately reflect stages and classes of human glioma. Many strategies developed and utilized here can also be applied more broadly to other CNS cancer models. Dr Van Dyke's laboratory has already developed a choroid plexus (CP) tumor model that is histologically similar to the human disease. It describes the CP model and the approaches used for its derivation. Dr Holland's work will define the cellular responses to genetic changes observed in human glioma by somatic gene introduction into the mouse brain. The Van Dyke lab will utilize germline modification strategies to generate mouse strains with similar alterations. Close interaction between Van Dyke and Holland will facilitate rapid identification of genetic changes to be engineered into the germline. Preliminary results from these labs indicate significant progress toward producing glioma- like pathologies in the mouse. Project 4 will establish a glial- specific targeted inactivation of the pTEN gene, a common inactivation in human glioma. This mouse will be used in model derivation, and Dr Louis will assess the extent to which pathologies induced in the mouse resemble those observed in humans. Histological and genetic studies in human and mouse samples will be pursued. The Louis lab will complete their isolation of the glioma-specific TSG, and the Van Dyke lab will use gene-targeting strategies to assess its tumor suppressor function. Finally, we will examine a limited number of therapeutic strategies in existing and developing mouse models, including EGFR-targeted strategies by Dr Holland and anti- angiogenesis gene therapy by Drs. Samulski and Van Dyke.